13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
33 檔
22.9%
At the close of Q1 2025, Sector Gamma As disclosed equity holdings valued at approximately $461.0M, spread across 33 reported holdings.
In Q1 2025, Sector Gamma As displayed an active expansion posture, initiating 33 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, PFE, BDX) accounted for 22.9% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 8.50% | -2.78% | +18.80% | |
| 2 | PFE | Pfizer Inc | Stock-Healthcare | 7.51% | -1.99% | -19.91% | |
| 3 | BDX | Becton Dickinson And Co | Stock-Healthcare | 6.02% | -0.01% | +7.89% | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 5.90% | +0.24% | -35.94% | |
| 5 | AMGN | Amgen Inc | Stock-Healthcare | 5.89% | -1.86% | +28.26% | |
| 6 | JNJ | Johnson & Johnson | Stock-Healthcare | 5.21% | — | +25.64% | |
| 7 | GILD | Gilead Sciences Inc | Stock-Healthcare | 5.02% | -1.75% | EXIT | |
| 8 | CVS | Cvs Health CORP | Stock-Healthcare | 4.38% | +1.19% | -6.91% | |
| 9 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 4.12% | -0.67% | -17.49% | |
| 10 | ELV | Elevance Health Inc | Stock-Healthcare | 4.01% | +0.69% | +66.55% | |
| 11 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.88% | -0.64% | — | |
| 12 | CNC | Centene CORP | Stock-Healthcare | 3.44% | +1.00% | +4.12% | |
| 13 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.11% | +0.46% | -36.81% | |
| 14 | INCY | Incyte CORP | Stock-Healthcare | 3.08% | -0.26% | -19.45% | |
| 15 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.86% | +0.05% | +24.24% | |
| 16 | BRKR | Bruker CORP | Stock-Healthcare | 2.83% | -0.18% | +33.34% | |
| 17 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.76% | +0.26% | +21.20% | |
| 18 | BAX | Baxter International Inc | Stock-Healthcare | 2.72% | — | +56.10% | |
| 19 | QGEN | Qiagen N.V. | Stock-Healthcare | 2.40% | — | — | |
| 20 | HUM | Humana Inc | Stock-Healthcare | 2.12% | -0.79% | EXIT | |
| 21 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.85% | — | +95.45% | |
| 22 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 1.60% | — | +72.29% | |
| 23 | GEHC | GE Healthcare Technology | Stock-Healthcare | 1.60% | +0.77% | +24.00% | |
| 24 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.51% | +0.56% | +41.38% | |
| 25 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.11% | -0.34% | — | |
| 26 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.08% | +0.56% | -17.83% | |
| 27 | BNTX | Biontech Se-adr | Stock-Other | 0.88% | — | -25.00% | |
| 28 | ASND | Ascendis Pharma A/S | Stock-Other | 0.85% | -1.15% | EXIT | |
| 29 | BIIB | Biogen Inc | Stock-Healthcare | 0.82% | -1.36% | -35.73% | |
| 30 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.78% | -1.67% | EXIT | |
| 31 | ACLXGBX | Arcellx Inc | Stock-Other | 0.74% | — | — | |
| 32 | SOLV | Solventum CORP | Stock-Healthcare | 0.73% | — | — | |
| 33 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.69% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 2 | PFE | Pfizer Inc | — | NEW | New buy |
| 3 | BDX | Becton Dickinson And Co | — | NEW | New buy |
| 4 | MDT | Medtronic plc | — | NEW | New buy |
| 5 | AMGN | Amgen Inc | — | NEW | New buy |
| 6 | JNJ | Johnson & Johnson | — | NEW | New buy |
| 7 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 8 | CVS | Cvs Health CORP | — | NEW | New buy |
| 9 | ZBH | Zimmer Biomet Holdings Inc | — | NEW | New buy |
| 10 | ELV | Elevance Health Inc | — | NEW | New buy |
| 11 | CAH | Cardinal Health Inc | — | NEW | New buy |
| 12 | CNC | Centene CORP | — | NEW | New buy |
| 13 | BMRN | Biomarin Pharmaceutical Inc | — | NEW | New buy |
| 14 | INCY | Incyte CORP | — | NEW | New buy |
| 15 | EW | Edwards Lifesciences CORP | — | NEW | New buy |
| 16 | BRKR | Bruker CORP | — | NEW | New buy |
| 17 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 18 | BAX | Baxter International Inc | — | NEW | New buy |
| 19 | QGEN | Qiagen N.V. | — | NEW | New buy |
| 20 | HUM | Humana Inc | — | NEW | New buy |
| 21 | THC | Tenet Healthcare CORP | — | NEW | New buy |
| 22 | ELAN | Elanco Animal Health Inc | — | NEW | New buy |
| 23 | GEHC | GE Healthcare Technology | — | NEW | New buy |
| 24 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 25 | TNDM | Tandem Diabetes Care Inc | — | NEW | New buy |
| 26 | BIO | Bio-rad Laboratories-a | — | NEW | New buy |
| 27 | BNTX | Biontech Se-adr | — | NEW | New buy |
| 28 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 29 | BIIB | Biogen Inc | — | NEW | New buy |
| 30 | LNTH | Lantheus Holdings Inc | — | NEW | New buy |
| 31 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 32 | SOLV | Solventum CORP | — | NEW | New buy |
| 33 | TGTX | Tg Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 33 disclosed positions in Q1 2025.
During Q1 2025, Sector Gamma As's top holdings by market value included BMY (8.5%)、PFE (7.5%)、BDX (6.0%). The largest single position, BMY, represented 8.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BMY
市值: $26.5M
In Q1 2025, Sector Gamma As made 33 total portfolio adjustments, initiating 33 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.